Amgen Inc (LTS:0R0T)
$ 269.5 0 (0%) Market Cap: 160.64 Bil Enterprise Value: 212.02 Bil PE Ratio: 38.26 PB Ratio: 21.34 GF Score: 90/100

Amgen Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:00PM GMT
Release Date Price: $304.5 (+0.91%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about the story going forward. So with that, I'll turn it over to Bob.

Robert A. Bradway
Amgen Inc. - Chairman, CEO & President

Okay. Good morning. Thank you, Chris, for your introduction, and thank you all for being here this morning. I would say heading into 2024 at Amgen, we're feeling very enthusiastic about the prospects of our being able to deliver attractive long-term growth for our shareholders and real value for the patients and staff at the company. So we're excited about the long-term outlook for our business, but also excited about what's in prospect in 2024.

Okay. You're familiar with the safe harbor statement. I'll move off that briskly. Let me just quickly remind you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot